CLLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cellectis SA (CLLS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has a declining price trend, and no recent trading signals from Intellectia Proprietary Trading Signals. While there is a positive analyst rating with a high price target, the technical indicators and lack of financial data do not support an immediate investment decision.
The MACD is negative and expanding (-0.0156), indicating bearish momentum. RSI is at 33.697, close to oversold territory but still neutral. Moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 3.48), with resistance levels at R1: 3.897 and R2: 4.025.
Analyst Bill Maughan initiated coverage with a Buy rating and a $9 price target, citing strong efficacy data for its CAR-T products in hematological cancers.
Price dropped by 4.38% in the last session, with no significant hedge fund or insider trading activity. Technical indicators suggest bearish momentum, and there is no recent news or congress trading data to support a positive sentiment.
No financial data or valuation metrics available for analysis.
Positive analyst sentiment with a Buy rating and a $9 price target, suggesting long-term growth potential based on the company's CAR-T product pipeline.
